Send to

Choose Destination
Bone Marrow Transplant. 2019 Feb;54(2):204-211. doi: 10.1038/s41409-018-0226-1. Epub 2018 May 24.

Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.

Author information

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Division of Biostatistics, Mayo Clinic, Scottsdale, AZ, USA.
Division of Palliative Care and Geriatric Medicine, Dana Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
Honor Health Cancer Care Network, Scottsdale, AZ, USA.
University of Texas Health San Antonio Cancer Center, San Antonio, TX, USA.


The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100% donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100% donor chimerism in CD33 fraction was present in 100% patients in FBM cohort, 90% in FluMel cohort while 44% in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2-4 and grade 3-4, was not statistically different in the 3 groups (BuFlu 47 and 35%, FBM 68 and 27%, FluMel 68 and 46%; pā€‰=ā€‰0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in patients who received FBM and FluMel.


Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center